tbuckley/cabot-search huggingface dataset:
Iyengar yoga compared to exercise in women with stage I-III breast cancer: Feasibility of therapeutic interventions during adjuvant cytotoxic or endocrine therapy.
Authors: Florian Wiedemann, Arndt Buessing, Martin Halle, Marion Kiechle, Nikola Kohls, Thomas Ostermann, Daniel Sattler, Johannes Ettl
Journal: Journal of Clinical Oncology (2013)

e20623 Background: Exercise and mind/body intervention studies have shown benefits when undertaken during cancer treatment. This ongoing trial aims to elucidate the different effects of yoga and conventional exercise on physical and psychological factors in breast cancer patients undergoing endocrine or cytotoxic therapy. This first interim analysis presents feasibility data comparing the two mentioned interventions. Methods: Patients are randomly assigned to receive Iyengar-yoga or conventional exercise on a 1:1 ratio during adjuvant therapy. The intervention consists of a weekly 60-minute yoga or physiotherapy exercise session together with individual home-based, self-contained 20-minute sessions twice a week. Data assessments via questionnaires are done at baseline, right after the 12-week intervention period and 2 months after the end of intervention. Patient accrual within two breast care units started in April 2011 with 66 patients being on study to date (2013, Jan 25). Results: So far, 57 patients (yoga: n=28; exercise: n=29) have completed the trial, while 9 patients dropped out (yoga: 5 patients; exercise: 4 patients). 46 patients received cytotoxic therapy (mean age: 48 y) and 11 patients received endocrine therapy (mean age: 60 y). 8 women participating either in yoga or exercise intervention were younger than 35 years (14%) and 6 women were older than 65 years (11%). Mean number of attended sessions is 9.0 (yoga: 9.3; exercise: 8.8; age &gt;65: 10.3). Overall 19 patients (33%) attended 11-12 out of 12 sessions (yoga: 32%; exercise: 35%; age &gt;65: 67%), 20 patients (35%) attended 8-10 sessions (yoga: 54%; exercise: 17%; age &gt;65: 17%), while 18 women (32%) participated only in 5-7 sessions (yoga: 14%; exercise: 48%; age &gt;65: 17%). 10 out of 51 participants accomplished 40 minutes of home-based training per week (yoga: 11%; exercise: 29%; age &gt;65: 50%). Conclusions: Yoga and exercise interventions are feasible during cancer treatment, although amount and frequency of training should be accommodated to individual condition. Both interventions seem to be practicable for elderly (&gt; 65 years) patients and for patients undergoing cytotoxic therapy.
USE OF ECHOCARDIOGRAPHIC GLOBAL LONGITUDINAL STRAIN IMAGING TO PREDICT IMPROVEMENT IN BALLOON AORTIC VALVULOPLASTY (BAV) PRIOR TO DEFINITIVE AORTIC VALVE REPLACEMENT
Authors: Mustafa Husaini, Yuko Soyama, Nobuyuki Kagiyama, Prashanth Thakker, Manoj Thangam, Nowrin Haque, Elena Deych, Marc Sintek, John M. Lasala, John Gorcsan, Alan Zajarias
Journal: Journal of the American College of Cardiology (2020)
METABOLIC RISK FACTORS IN FIRST ACS (MERIFACS): INTERIM RESULTS OF A MULTICENTER STUDY
Authors: Hygriv B. Rao, Ramaraju S. Namagiri, C.S. Raju, Pushparaj Patel, Annaji Rao, Sadiq Md Azam, Sudhindra Vooturi
Journal: Journal of the American College of Cardiology (2020)
MYOCARDIAL DYNAMICS AND RIGHT HEART PRESSURES CORRELATION AFTER HEART TRANSPLANTATION
Authors: Roberto Sarnari, Ashitha Pathrose, Allison Blake, Muhannad Abbasi, Julie Blaisdell, Kambiz Ghafourian, Jane Wilcox, Sadiya Khan, Esther Vorovich, Jonathan Rich, Allen S. Anderson, Clyde Yancy, James C. Carr, Michael Markl
Journal: Journal of the American College of Cardiology (2020)
MULTI-VARIABLE ANALYSIS OF ECHOCARDIOGRAPHIC PARAMETERS IN PATIENTS PRIOR TO AND AFTER GASTRIC SLEEVE SURGERY
Authors: Sajjad Haider, Atif Tatari, Caitlyn E. Galloway, Muhammad T. Amjad, Douglas M. McElroy, Onyeoziri R. Nwanguma, Eric Darnell, Brandy Emery, Aniruddha Singh, Jacqueline Dowe
Journal: Journal of the American College of Cardiology (2020)
Integrative Omics Analysis Reveals Soluble Cadherin-3 as a Survival Predictor and an Early Monitoring Marker of EGFR Tyrosine Kinase Inhibitor Therapy in Lung Cancer
Authors: Ting-Feng Hsiao, Chih-Liang Wang, Yi-Cheng Wu, Hsiang-Pu Feng, Yen-Chuan Chiu, Hao-Yu Lin, Ko-Jiunn Liu, Gee-Chen Chang, Kun-Yi Chien, Jau-Song Yu, Chia-Jung Yu
Journal: Clinical Cancer Research (2020)

Abstract Purpose: EGFR tyrosine kinase inhibitors (EGFR-TKI) benefit patients with advanced lung adenocarcinoma (ADC) harboring activating EGFR mutations. We aimed to identify biomarkers to monitor and predict the progression of patients receiving EGFR-TKIs via a comprehensive omic analysis. Experimental Design: We applied quantitative proteomics to generate the TKI resistance–associated pleural effusion (PE) proteome from patients with ADC with or without EGFR-TKI resistance. Candidates were selected from integrated genomic and proteomic datasets. The PE (n = 33) and serum (n = 329) levels of potential biomarkers were validated with ELISAs. Western blotting was applied to detect protein expression in tissues, PEs, and a cell line. Gene knockdown, TKI treatment, and proliferation assays were used to determine EGFR-TKI sensitivity. Progression-free survival (PFS) and overall survival (OS) were assessed to evaluate the prognostic values of the potential biomarkers. Results: Fifteen proteins were identified as potential biomarkers of EGFR-TKI resistance. Cadherin-3 (CDH3) was overexpressed in ADC tissues compared with normal tissues. CDH3 knockdown enhanced EGFR-TKI sensitivity in ADC cells. The PE level of soluble CDH3 (sCDH3) was increased in patients with resistance. The altered sCDH3 serum level reflected the efficacy of EGFR-TKI after 1 month of treatment (n = 43). Baseline sCDH3 was significantly associated with PFS and OS in patients with ADC after EGFR-TKI therapy (n = 76). Moreover, sCDH3 was positively associated with tumor stage in non–small cell lung cancer (n = 272). Conclusions: We provide useful marker candidates for drug resistance studies. sCDH3 is a survival predictor and real-time indicator of treatment efficacy in patients with ADC treated with EGFR-TKIs.
LARGER ORGANIZED AREAS IN PERSISTENT ATRIAL FIBRILLATION PREDICTS TERMINATION DURING ABLATION
Authors: Namita Ravi, Albert J. Rogers, Neal Bhatia, Jagteshwar S. Tung, David Krummen, William Sauer, Mahmood Alhusseini, Tina Baykaner, Paul Wang, Wouter-Jan Rappel, Sanjiv Narayan
Journal: Journal of the American College of Cardiology (2020)
Plasminogen glycoforms alteration and activation susceptibility associated with the missense variant p.Lys330Glu in HAE‐PLG patients
Authors: Faidra Parsopoulou, Delphine Charignon, Maud Tengo, Fotis Psarros, Coen Maas, Teresa Gonzalez‐Quevedo, Christian Drouet, Anastasios E. Germenis, Arije Ghannam
Journal: Allergy (2020)
OBESITY: FRIEND OR FOE IN SINGLE-VESSEL CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION?
Authors: Rupak Desai, Ahmed Mahmood, Rushikkumar Bhuva, Hee Kong Fong, Muhammad Uzair Lodhi, Nanush Damarlapally, Kishorbhai Gangani, Rajesh Sachdeva, Gautam Kumar
Journal: Journal of the American College of Cardiology (2020)
EFFECT OF TREATMENT WITH DAPAGLIFLOZIN IS CONSISTENT ACROSS THE RANGE OF BODY MASS INDEX IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL
Authors: Pardeep Jhund, Carly Adamson, Silvio E. Inzucchi, Mikhail Kosiborod, Anna Maria Langkilde, Felipe Martinez, Olof Bengtsson, Piotr Ponikowski, Marc Sabatine, Mikaela Sjoestrand, Scott D. Solomon, John McMurray
Journal: Journal of the American College of Cardiology (2020)
ALIROCUMAB AND CARDIOVASCULAR OUTCOMES IN WOMEN AFTER AN ACUTE CORONARY SYNDROME: AN ODYSSEY OUTCOMES TRIAL ANALYSIS
Authors: Vera Bittner, Jennifer McGinniss, Gregory G. Schwartz, Deepak Bhatt, Terrance Chua, H. Asita de Silva, Rafael Diaz, Maria Dorobantu, Shaun Goodman, Robert A. Harrington, Johan Wouter Jukema, Yong-Un Kim, Robert Pordy, Matthew Roe, Michael Szarek, Harvey White, Andreas M. Zeiher, Philippe Gabriel Steg
Journal: Journal of the American College of Cardiology (2020)
Race modifies default mode connectivity in Alzheimer’s disease
Authors: Maria B. Misiura, J. Christina Howell, Junjie Wu, Deqiang Qiu, Monica W. Parker, Jessica A. Turner, William T. Hu
Journal: Translational Neurodegeneration (2020)

Abstract Background Older African Americans are more likely to develop Alzheimer’s disease (AD) than older Caucasians, and this difference cannot be readily explained by cerebrovascular and socioeconomic factors alone. We previously showed that mild cognitive impairment and AD dementia were associated with attenuated increases in the cerebrospinal fluid (CSF) levels of total and phosphorylated tau in African Americans compared to Caucasians, even though there was no difference in beta-amyloid 1–42 level between the two races. Methods We extended our work by analyzing early functional magnetic resonance imaging (fMRI) biomarkers of the default mode network in older African Americans and Caucasians. We calculated connectivity between nodes of the regions belonging to the various default mode network subsystems and correlated these imaging biomarkers with non-imaging biomarkers implicated in AD (CSF amyloid, total tau, and cognitive performance). Results We found that race modifies the relationship between functional connectivity of default mode network subsystems and cognitive performance, tau, and amyloid levels. Conclusion These findings provide further support that race modifies the AD phenotypes downstream from cerebral amyloid deposition, and identifies key inter-subsystem connections for deep imaging and neuropathologic characterization.
CLONAL HEMATOPOIESIS ASSOCIATED MUTATIONS, CARDIOVASCULAR EVENTS, AND ALL-CAUSE DEATH AMONG PATIENTS WITH ACUTE MYELOID LEUKEMIA
Authors: Oscar Calvillo Argüelles, Alice Schöffel, Montserrat Carrillo Estrada, Husam Abdel-Qadir, Georgina Daher Reyes, Vikas Gupta, Aaron Schimmer, Andre Schuh, Paaladinesh Thavendiranathan
Journal: Journal of the American College of Cardiology (2020)
Manageable safety profile in patients with taxane-resistant metastatic breast cancer (MBC) treated with ixabepilone: Final report
Authors: M. N. Fornier, M. Martin, J. Klimovsky, C. A. Bunnell
Journal: Journal of Clinical Oncology (2006)

10587 Background: The epothilones, a new class of antineoplastic agents, promote tumor cell death by stabilizing microtubules and inducing apoptosis. Ixabepilone was selected from over 300 epothilone analogs due to its high in vivo efficacy, good metabolic stability and low protein binding. Methods: This international, multicenter, open-label Phase II trial was designed to assess the activity of ixabepilone in patients (pts) with highly resistant MBC who had progressed following taxane treatment. Eligible pts were aged ≥18 years with MBC (progressed on or within 4 months of taxane therapy [or within 6 months if adjuvant taxane only]). Pts were excluded if they had had ≥3 prior chemotherapy regimens for MBC or had ≥Grade 2 neuropathy. Ixabepilone (40 mg/m 2 q3w) was administered as a 3-hour infusion for a maximum of 18 cycles, unless there was evidence of progressive disease and/or pts met discontinuation criteria. Toxicity was evaluated continuously. Results: Of 49 pts (median age 54 years, range 30–81), 86% of pts had received ≥2 prior chemotherapy regimens. Treatment-related adverse events (TRAEs) were manageable and mostly Grade 1 or 2 (45%). Treatment-related neuropathy was mostly sensory, mild-to-moderate, cumulative and reversible. Sensory neuropathy was managed mainly with dose reductions (12 out of 49 pts had their dose reduced due to neuropathy). Treatment-limiting or severe neuropathy generally resolved or lessened in intensity within 1–2 months after therapy discontinuation. Febrile neutropenia was reported in only 2 pts, in addition, 2 pts (4%) developed treatment-related infection with neutropenia. Only six pts (12%) required growth factor support for neutropenia during their treatment. Progressive disease was the most common reason for discontinuing the study (36%), with 16% discontinuing due to TRAEs. Conclusions: Ixabepilone demonstrates an acceptable safety profile, along with promising antitumor activity, in pts with clearly defined taxane-resistant MBC. [Table: see text] [Table: see text]
SPORT-SPECIFIC PERFORMANCE ASSESSMENT
Authors: Csulak Emese, Nora Sydo, István Györe, Tibor Sydó, Iván Petrov, Dávid Major, Bálint Károly Lakatos, Attila Kovács, Csilla Czimbalmos, Hajnalka Vágó, Bela Merkely
Journal: Journal of the American College of Cardiology (2020)
ASYMMETRIC AND SYMMETRIC DIMETHYLARGININE ARE INEDEPENDENTLY ASSOCIATED WITH STROKE, BLEEDING AND DEATH IN ANTICOAGULATED PATIENTS WITH ATRIAL FIBRILLATION
Authors: Tymon Pol, Ziad Hijazi, Johan Westerbergh, Johan Lindbäck, John H. Alexander, Rafaele De Caterina, Christopher B. Granger, Tamila Heresztyn, Philippe Gabriel Steg, Renato Lopes, Agneta Siegbahn, John Horowitz, Lars Wallentin
Journal: Journal of the American College of Cardiology (2020)
Treatment of chemoresistant ovarian cancer with sigma2/SMAC and cisplatin.
Authors: Ivy Wilkinson-Ryan, Dirk Spitzer, Robert Mach, Suwanna Vangveravong, Peter S Goedegebuure, Yassar Hashim, Stacey Plambeck-Suess, Matthew A. Powell, David Gardner Mutch, William G. Hawkins
Journal: Journal of Clinical Oncology (2013)

e16508 Background: Platinum resistance continues to be a major barrier to the successful treatment of ovarian cancer. Overexpression of the X-linked inhibitor of apoptosis proteins (XIAP) contribute to platinum resistance in ovarian cancer through inhibition of caspases and up regulation of Akt activity. Second mitochondrial-derived activators of caspases (SMAC) is an endogenous protein that binds to and reverses XIAP-mediated inhibition of caspases. In order to exploit the SMAC-mediated pro-apoptotic pathway pharmacologically, SMAC mimetics have been developed and shown to induce apoptosis in cancer cells in vitro and in vivo. Untargeted cytotoxic cancer drugs bind to both malignant and normal tissue leading to significant toxicity. We have shown previously that solid tumors upregulate the sigma-2 receptor. We have also shown that sigma-2 ligands are internalized into cancer cells and are therefore an appealing vehicle for tumor targeted therapy. The goal of this study is to test if a conjugate drug of sigma-2 ligand and a SMAC mimetic (sigma-2/SMAC) in combination with chemotherapy is capable of overcoming chemoresistance in ovarian cancer. Methods: SKOV3 and OVCAR3 ovarian cancer cell lines were treated with sigma2/SMAC (1-16μM) and/or cisplatin (.5-10μg/mL). Viability assays were used to detect cell death. Luminescence-based caspase assays were used to compare the activity of caspase-3, -7, and -9 between treatment groups to document involvement of the XIAP survival pathway. Results: We found that sigma2-SMAC is synergistic when used in combination with cisplatin. Compared to untreated cells, SKOV3 cells treated with sigma/2SMAC (4uM), cisplatin .5ug/mL, or combination therapy showed 52.6%, 117.7%, and 34.8% viability respectively (p&lt;.05). Cisplatin and sigma2/SMAC remained synergistic at increasing doses. Similar results were observed in OVCAR3 cells. Caspase-3 and -7 increased in combination therapy 1.2-fold over Sigma/2SMAC alone (4uM) and 7-fold over cisplatin alone (.5ug/mL) in SKOV3 cells (p&lt;.05). Conclusions: This study suggests that the sigma2/SMAC conjugate provides a targeted means for overcoming chemoresistance in ovarian cancer through inhibition of XIAP and activation of caspases.
Massive Splenomegaly from Disseminated <i>Mycobacterium avium–intracellulare</i> Infection
Authors: Lucas R Massoth, Abner Louissaint
Journal: New England Journal of Medicine (2020)

A 29-year-old man with HIV infection presented with abdominal pain and drenching nights sweats. Computed tomography of the abdomen revealed massive splenomegaly caused by disseminated Mycobacterium avium–intracellulare infection.
Strategies to increase efficiency in protocol development.
Authors: Kati M Stoermer
Journal: Journal of Clinical Oncology (2012)

e16508 Background: In 2010, the NCI’s Operational Efficiency Working Group recommended changes aimed at compressing the timeline for cancer clinical trial activation. SWOG implemented multiple changes prior to and since that report, intended to increase protocol development efficiency. Two protocol development interventions were piloted; weekly meetings of SWOG leadership and the study team, or SWOG Activation Team (“SWAT”), which began in 2007, and intensive RaPID Protocol Development Meetings, beginning in 2010. Methods: The highest priority developing trial was selected for SWAT, with only one trial using this mechanism at a time. RaPID trials were chosen based on trial complexity and urgency. We reviewed all protocol development milestones across SWOG protocols activated between 2007 and 2011. Results of the review were compared and contrasted for 1) the two piloted interventions 2) pre- and post-OEWG implementation and 3) time from trial activation to first patient entered. Results: Time to activation results are outlined in the table. Within SWAT, the median time to activation was 400 days, 190 days sooner that all trials developed in the same time period. RaPID trials median time to activation was 225 days, 365 days sooner than others developed in the same timeframe. Regardless of intervention type, median time from concept submission to trial activation was 724 days pre-OEWG and 286 days post-OEWG. The median time from trial activation to first patient accrued was 106 days pre-OEWG implementation and 75 days post-OEWG. Conclusions: While barriers to timely trial activation still exist, SWOG programs aimed at enhancing the efficiency of protocol development, in partnership with the implemented OEWG recommendations, have been successful. SWOG has developed effective and timely protocol develop strategies among diverse, and geographically dispersed, study teams with only modest increases in effort and cost. Supported in part by PHS Cooperative Agreement grant awarded by the National Cancer Institute, DHHS: CA032102. [Table: see text]
Endocrine-Disrupting Chemicals in Cosmetics
Authors: Andrea C. Gore, Barbara Cohn
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
DEVELOPMENT AND CLINICAL APPLICATION OF AN ENZYME-LINKED IMMUNOSORBENT ASSAY FOR OXIDIZED HIGH DENSITY LIPOPROTEIN
Authors: Takeshi Okada, Tohru Ohama, Ayami Saga, Hiroyasu Inui, Kotaro Kanno, Masahiro Koseki, Makoto Nishida, Hasashi Sakata, Shizuya Yamashita
Journal: Journal of the American College of Cardiology (2020)
Development and validation of nomograms to accurately predict risk of recurrence for patients with laryngeal squamous cell carcinoma: Cohort study
Authors: Jie Cui, Liping Wang, Guangmou Tan, Weiquan Chen, Guangmin He, Haiyan Huang, Zhen Chen, Hong Yang, Jie Chen, Genglong Liu
Journal: International Journal of Surgery (2020)

Recurrence is still major obstacle to long-term survival in laryngeal squamous cell carcinoma (LSCC). We aimed to establish and validate a nomogram to precisely predict recurrence probability in patients with LSCC.A total of 283 consecutive patients with LSCC received curative-intend surgery between 2011 and 2014 at were enrolled in this study. Subsequently, 283 LSCC patients were randomly assigned to a training cohort (N = 171) and a validation cohort (N = 112) in a 3:2 ratio. According to the results of multivariable Cox regression analysis in the training cohort, we developed a nomogram. The predictive accuracy and discriminative ability of the nomogram were evaluated by calibration curve and concordance index (C-index), and compared with TNM stage system by C-index, receiver operating characteristic (ROC) analysis. Decision curve analysis (DCA) was performed to estimate clinical value of our nomogram.Six independent factors rooted in multivariable analysis of the training cohort to predict recurrence were age, tumor site, smoking, alcohol, N stage and hemoglobin, which were all integrated into the nomogram. The calibration curve for the probability of recurrence presented that the nomogram-based predictions were in good correspondence with actual observations. The C-index of the nomogram was 0.81 (0.75-0.88), and the area under curve (AUC) of nomogram in predicting recurrence free survival (RFS) was 0.894, which were significantly better than traditional TNM stage. Decision curve analysis further affirmed that our nomogram had a larger net benefit than TNM stage. The results were confirmed in the validation cohort.A risk prediction nomogram for patients with LSCC, incorporating readily assessable clinicopathologic variables, generates more accurate estimations of the recurrence probability when compared TNM stage alone, but still needs additional data before being used in clinical implications.
VALIDATION OF AN ANP DEFICIENCY IN ACUTE DECOMPENSATED HEART FAILURE THROUGH ANALYSES OF BIOLOGICALLY IN-ACTIVE NATRIURETIC PEPTIDES
Authors: Shawn Reginauld, Seethalakshmi Iyer, Yang Chen, Xiao Ma, Jeson Sangaralingham, John Burnett
Journal: Journal of the American College of Cardiology (2020)